DK3463328T3 - Seladelpar til behandling af primær biliær cholangitis - Google Patents

Seladelpar til behandling af primær biliær cholangitis Download PDF

Info

Publication number
DK3463328T3
DK3463328T3 DK17722943.2T DK17722943T DK3463328T3 DK 3463328 T3 DK3463328 T3 DK 3463328T3 DK 17722943 T DK17722943 T DK 17722943T DK 3463328 T3 DK3463328 T3 DK 3463328T3
Authority
DK
Denmark
Prior art keywords
seladelpar
treatment
primary biliary
biliary cholangitis
cholangitis
Prior art date
Application number
DK17722943.2T
Other languages
Danish (da)
English (en)
Inventor
Pol Boudes
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Application granted granted Critical
Publication of DK3463328T3 publication Critical patent/DK3463328T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17722943.2T 2016-05-31 2017-04-26 Seladelpar til behandling af primær biliær cholangitis DK3463328T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (1)

Publication Number Publication Date
DK3463328T3 true DK3463328T3 (da) 2022-07-04

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17722943.2T DK3463328T3 (da) 2016-05-31 2017-04-26 Seladelpar til behandling af primær biliær cholangitis

Country Status (27)

Country Link
US (5) US10272058B2 (https=)
EP (1) EP3463328B1 (https=)
JP (1) JP7079735B2 (https=)
KR (1) KR102408288B1 (https=)
CN (2) CN121466055A (https=)
AU (1) AU2017274293B2 (https=)
BR (1) BR112018074147A2 (https=)
CA (1) CA3024155C (https=)
CY (1) CY1125465T1 (https=)
DK (1) DK3463328T3 (https=)
ES (1) ES2921230T3 (https=)
HR (1) HRP20220903T1 (https=)
HU (1) HUE059838T2 (https=)
IL (1) IL263372B2 (https=)
LT (1) LT3463328T (https=)
MX (1) MX390417B (https=)
NZ (1) NZ748721A (https=)
PL (1) PL3463328T3 (https=)
PT (1) PT3463328T (https=)
RS (1) RS63345B1 (https=)
RU (1) RU2765460C2 (https=)
SG (1) SG11201810123SA (https=)
SI (1) SI3463328T1 (https=)
SM (1) SMT202200471T1 (https=)
UA (1) UA122719C2 (https=)
WO (1) WO2017209865A1 (https=)
ZA (1) ZA201808360B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3880185A1 (en) * 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Combination treatment of nafld and nash
US20220241228A1 (en) 2021-02-01 2022-08-04 Cymabay Therapeutics, Inc. Treatment of cholangiopathies
WO2024180642A1 (ja) 2023-02-28 2024-09-06 株式会社日立ハイテク プラズマ処理装置およびプラズマ処理装置の試料台の製造方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
WO1996027606A1 (en) 1995-03-06 1996-09-12 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
NZ331217A (en) 1996-02-14 2000-02-28 Novartis Ag Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CA2740874C (en) 2008-10-17 2018-02-27 Metabolex, Inc. Use of ppar.gamma.agonists to reduce small dense ldl particles
SG175390A1 (en) * 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ602125A (en) 2010-03-30 2014-01-31 Novartis Ag Uses of dgat1 inhibitors
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR102374499B1 (ko) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
EP3160458A1 (en) 2014-06-26 2017-05-03 Cymabay Therapeutics, Inc. Treatment of severe hypertriglyceridemia
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
DK3973959T3 (da) 2017-09-26 2025-01-20 Cymabay Therapeutics Inc Behandling af kolestatisk kløe med seladelpar
EP3880187A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
EP3880185A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Combination treatment of nafld and nash

Also Published As

Publication number Publication date
PT3463328T (pt) 2022-07-07
RU2018146504A (ru) 2020-07-09
US20210000774A1 (en) 2021-01-07
JP2019518022A (ja) 2019-06-27
HRP20220903T1 (hr) 2022-10-14
CY1125465T1 (el) 2025-05-09
US20200061006A1 (en) 2020-02-27
CN121466055A (zh) 2026-02-06
SG11201810123SA (en) 2018-12-28
JP7079735B2 (ja) 2022-06-02
US20190255004A1 (en) 2019-08-22
CA3024155C (en) 2023-10-10
KR102408288B1 (ko) 2022-06-10
PL3463328T3 (pl) 2022-10-03
US20210220305A1 (en) 2021-07-22
WO2017209865A1 (en) 2017-12-07
MX2018014915A (es) 2019-04-24
AU2017274293A1 (en) 2018-12-13
EP3463328A1 (en) 2019-04-10
RU2765460C2 (ru) 2022-01-31
RU2018146504A3 (https=) 2020-07-27
BR112018074147A2 (pt) 2019-03-06
HUE059838T2 (hu) 2023-01-28
AU2017274293B2 (en) 2022-03-31
US20170340589A1 (en) 2017-11-30
SMT202200471T1 (it) 2023-01-13
SI3463328T1 (sl) 2022-08-31
LT3463328T (lt) 2022-08-10
ES2921230T3 (es) 2022-08-22
CN109195594A (zh) 2019-01-11
US10272058B2 (en) 2019-04-30
MX390417B (es) 2025-03-20
UA122719C2 (uk) 2020-12-28
IL263372B2 (en) 2023-06-01
RS63345B1 (sr) 2022-07-29
US11000494B2 (en) 2021-05-11
ZA201808360B (en) 2020-02-26
US10813895B2 (en) 2020-10-27
US11596614B2 (en) 2023-03-07
EP3463328B1 (en) 2022-06-15
US10478411B2 (en) 2019-11-19
CA3024155A1 (en) 2017-12-07
KR20190015363A (ko) 2019-02-13
NZ748721A (en) 2022-04-29
IL263372A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
CY2025027I2 (el) Ελαφιμπρανορη για χρηση στην αντιμετωπιση πρωτοπαθους χολικης χολαγγειτιδας
DK3501542T3 (da) Esketamin til behandling af depression
DK3728271T3 (da) Makrocykliske forbindelser til behandling af sygdomme
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3143025T3 (da) Forbindelser til behandling af spinal muskelatrofi
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3524255T3 (da) Sammensætning til behandling af acne
DK3506904T3 (da) Behandling af demens
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
ZA201903649B (en) Treatment for primary biliary cholangitis
DK3324824T3 (da) Fremgangsmåde til behandling af binokulare dysfunktioner
DK3318115T3 (da) Maskine til behandling af svinegylle
DK3430143T3 (da) Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
DK3573620T3 (da) Sammensætninger til behandling af hypertension
DK3463328T3 (da) Seladelpar til behandling af primær biliær cholangitis
DK3261661T3 (da) Menotropin til behandling af infertilitet
DK3515455T3 (da) Forbindelser til behandling af lidelser i lipoproteinmetabolismen
DK3638293T3 (da) Sammensætninger til behandling af cancer